{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:16:01Z","timestamp":1794960961624,"version":"4.9.1"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Anaphylaxis is a potentially life-threatening multi-system allergic reaction to a biological trigger resulting in the release of potent inflammatory mediators from mast cells and basophils and causing symptoms in at least two organ systems that generally include skin, lungs, heart, or gastrointestinal tract in any combination. One exception is profound hypotension as an isolated symptom. There are two types of triggers of anaphylaxis: immunologic and non-Immunologic. Immunologic anaphylaxis is initiated when a foreign antigen directly binds to IgE expressed on mast cells or basophils and induces the release of histamine and other inflammatory substances resulting in vasodilation, vascular leakage, decreased peripheral vascular resistance, and heart muscle depression. If left untreated, death by shock (profound hypotension) or asphyxiation (airway obstruction) can occur. The non-immunologic pathway, on the other hand, can be initiated in many ways. A foreign substance can directly bind to receptors of mast cells and basophils leading to degranulation. There can be immune complex activation of the classical complement cascade with the release of anaphylatoxins C3a and C5a with subsequent recruitment of mast cells and basophils. Finally, hyperosmolar contrast agents can cause blood cell lysis, enzyme release, and complement activation, resulting in anaphylactoid (anaphylactic-like) symptoms. In this report we emphasize the recruitment of the bradykinin-forming cascade in mast cell dependent anaphylactic reactions as a potential mediator of severe hypotension, or airway compromise (asthma, laryngeal edema). We also consider airway obstruction due to inhibition of angiotensin converting enzyme with a diminished rate of endogenous bradykinin metabolism, leading not only to laryngeal edema, but massive tongue swelling with aspiration of secretions.<\/jats:p>","DOI":"10.3389\/falgy.2024.1302605","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:28:00Z","timestamp":1706156880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The bradykinin-forming cascade in anaphylaxis and ACE-inhibitor induced angioedema\/airway obstruction"],"prefix":"10.3389","volume":"5","author":[{"given":"Berhane","family":"Ghebrehiwet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusumam","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen P.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B2","first-page":"463","article-title":"The discovery of anaphylaxis, a brief but triumphant encounter of two physiologists","volume":"37","author":"Richet","year":"2003","journal-title":"Hist Sci Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaci.2013.06.015","article-title":"Anaphylaxis: clinical patterns, mediator release, and severity","volume":"132","author":"Brown","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-800100-4.00002-7","article-title":"Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway","volume":"121","author":"Kaplan","year":"2014","journal-title":"Adv Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.anai.2010.01.007","article-title":"The bradykinin-forming cascade and its role in hereditary angioedema","volume":"109","author":"Kaplan","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jaci.2022.08.022","article-title":"Concise update on the pathogenesis of chronic spontaneous urticaria (CSU)","volume":"150","author":"Hide","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Eng J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaci.2016.09.051","article-title":"Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema","volume":"140","author":"Straka","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1182\/blood.V63.6.1453.1453","article-title":"In vitro activation of the contact (hageman factor) system of plasma by heparin and chondroitin sulfate E","volume":"63","author":"Hojima","year":"1984","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2222.1997.tb01193.x","article-title":"Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions","volume":"27","author":"Brunnee","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000024284","article-title":"Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system","volume":"120","author":"Noga","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1538-7836.2010.03832.x","article-title":"Platelet polyphosphate: an endogenous activator of coagulation factor XII","volume":"8","author":"MacMan","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jth.12295","article-title":"Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates","volume":"11","author":"Puy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","first-page":"28435","DOI":"10.1074\/jbc.M112.385823","article-title":"Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcisomes","volume":"287","author":"Moreno-Sanchez","year":"2012","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cea.13558","article-title":"Evidence for bradykinin release in chronic spontaneous urticaria","volume":"50","author":"Hofman","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2014.07.057","article-title":"Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions","volume":"135","author":"Sala-Cunill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.immuni.2011.02.008","article-title":"Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo","volume":"34","author":"Oschatz","year":"2011","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B21","first-page":"184","article-title":"Diagnosis and treament of chronic spontaneous urticaria","volume":"39","author":"Kaplan","year":"2020","journal-title":"Allergy News Views Algorithms Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"134","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0306-3623(83)90001-0","article-title":"Pharmacology of kinins: their relevance to tissue injury and inflammation","volume":"14","author":"Marceau","year":"1983","journal-title":"Gen Pharmacol"},{"key":"B24","first-page":"540","article-title":"The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model","volume":"100","author":"Bleeker","year":"1982","journal-title":"J Lab Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/blood.V82.6.1732.1732","article-title":"Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock","volume":"82","author":"van der Linden","year":"1993","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1172\/JCI109936","article-title":"Physiologic manifestations of human anaphylaxis","volume":"66","author":"Smith","year":"1980","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1398-9995.2008.01733.x","article-title":"Epinephrine: the drug of choice for anaphylaxis. A statement of the world allergy organization","volume":"63","author":"Kemp","year":"2008","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.jaip.2023.04.037","article-title":"Refractory anaphylaxis: a new entity for severe anaphylaxis","volume":"11","author":"Pouessel","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N Eng J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2012.08.016","article-title":"Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis","volume":"131","author":"Vadas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin receptor antogonist in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Eng J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","article-title":"Specific targeting of plasma kallikrein for treatment of hereditary angioedema: a revolutionary decade","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14680","article-title":"Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study","volume":"76","author":"Lumry","year":"2021","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2020.01.043","article-title":"Preventing anaphylaxis fatalities: should we target bradykinin?","volume":"145","author":"Kaplan","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency dpartment","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jaad.2004.09.032","article-title":"Angioedema","volume":"53","author":"Kaplan","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"B41","first-page":"153","article-title":"Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema","volume":"136","author":"Sabroe","year":"1997","journal-title":"Br J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0735-6757(93)90166-9","article-title":"Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors","volume":"11","author":"Pigman","year":"1993","journal-title":"Am J Emergency Medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angioedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Clinical practice. Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N Eng J Med"},{"key":"B45","first-page":"374","article-title":"A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin","volume":"214","author":"Yang","year":"1970","journal-title":"Biochem Biophys Acta"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/2151402a0","article-title":"Second kininase in human blood plasma","volume":"215","author":"Yang","year":"1967","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/0006-2952(86)90726-4","article-title":"Studies of the digestion of bradykinin, lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme","volume":"35","author":"Sheikh","year":"1986","journal-title":"Biochem Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0006-2952(62)90119-3","article-title":"An enzyme in human plasma that inactivates bradykinin and kallidins","volume":"11","author":"Erdos","year":"1962","journal-title":"Biochem Pharmacol"},{"key":"B49","first-page":"357","article-title":"The B1 receptors for kinins","volume":"50","author":"Marceau","year":"1998","journal-title":"Pharmacol Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/bj3300361","article-title":"Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B1 receptor gene expression","volume":"330","author":"Zhou","year":"1998","journal-title":"Biochem J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4049\/jimmunol.1302031","article-title":"Soluble gC1qR is an autocrine signal that induces B1R expression on endothelial cells","volume":"192","author":"Ghebrehiwet","year":"2014","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0162-3109(99)00133-2","article-title":"Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"43","author":"Blais","year":"1999","journal-title":"Immunopharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1126\/science.175444","article-title":"Angiotensin-converting enzyme: vascular endothelial localization","volume":"191","author":"Caldwell","year":"1976","journal-title":"Science"},{"key":"B55","first-page":"72","article-title":"Converting enzyme and bradykininase in the lung","volume":"31","author":"Alabaster","year":"1972","journal-title":"Circ Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1074\/jbc.M709837200","article-title":"Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists","volume":"283","author":"Zhang","year":"2008","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.anai.2011.02.012","article-title":"DPP-4 inhibitors and angioedema: a cause for concern?","volume":"106","author":"Byrd","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","article-title":"Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors","volume":"359","author":"Adam","year":"2002","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"B60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0091-6749(96)70151-3","article-title":"Increased sensitivity to bradykinin among African Americans","volume":"98","author":"Gainer","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertension"},{"key":"B62","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/jb\/93.3.833","article-title":"Characterization of human salivary kallikrein: reactivities to human plasma kininogens and proteinase inhibitors","volume":"93","author":"Sakamoto","year":"1983","journal-title":"J Biochem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1067\/mai.2002.121316","article-title":"Pathways for bradykinin formation and inflammatory disease","volume":"109","author":"Kaplan","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1160\/TH06-03-0128","article-title":"Plasma levels of bradykinin are suppressed in factor XII-deficient mice","volume":"95","author":"Iwaki","year":"2006","journal-title":"Thromb Haemost"},{"key":"B65","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1016\/S0021-9258(17)39515-7","article-title":"Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininog","volume":"260","author":"Takagaki","year":"1985","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1055\/s-0040-1701238","article-title":"Lisinopril-induced angioedema in a patient with plasma prekallikrein deficiency","volume":"4","author":"Desgupta","year":"2020","journal-title":"TH Open"},{"key":"B67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1201\/b14212-12","article-title":"Characterization of complement anaphylaxtoxins and their biological response","volume-title":"The Human Complement System in Health and Disease","author":"Ember","year":"1998"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1084\/jem.181.6.2119","article-title":"C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation","volume":"181","author":"Daffern","year":"1995","journal-title":"J Exp Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4049\/jimmunol.156.3.1256","article-title":"Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and\/or IgG4) in the complement-activating capacity of immune complexes","volume":"156","author":"Bergamaschini","year":"1996","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1248\/bpb.b22-00766","article-title":"Lipopolysaccharide priming exacerbates anaphylatoxin C5a-induced anaphylaxis in mice","volume":"46","author":"Yasuda","year":"2023","journal-title":"Biol Parm Bull"},{"key":"B74","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"Kuhn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1099\/mic.0.046862-0","article-title":"Interaction of Bacteroides fragilis and Bacteroides thetaiotaomicron with the kallikrein\u2013kinin system","volume":"157","author":"Murphy E","year":"2011","journal-title":"Microbiology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.4049\/jimmunol.177.12.8723","article-title":"Induction of vascular leakage and blood pressure lowering through kinin release by a serine proteinase from Aeromonas sobria","volume":"177","author":"Imamura","year":"2006","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2013a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60228-X","article-title":"Anaphylatoxins: C3a and C5a","volume":"26","author":"Hugli","year":"1978","journal-title":"Adv Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/srep01932","article-title":"Intravital analysis of vascular permeability in mice using two-photon microscopy","author":"Egawa","year":"2013","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/biomedicines9040439","article-title":"In vitro investigation of vascular permeability in endothelial cells from human artery, vein and lung microvessels at steady-state and anaphylactic conditions","volume":"9","author":"Callesen","year":"2021","journal-title":"Biomedicines"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.836222","article-title":"Pathophysiological, cellular, and molecular events of the vascular system in anaphylaxis","volume":"13","author":"Nu\u00f1ez-Borque","year":"2022","journal-title":"Front Immun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Eng J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Eng J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaci.2007.02.012","article-title":"Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)","volume":"119","author":"Bork","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N Eng J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJM199512073332316","article-title":"Angioedema induced by the angiotensin II blocker losartan","volume":"333","author":"Acker","year":"1995","journal-title":"N Eng J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2007","journal-title":"Circulation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1046\/j.1523-1755.2000.00877.x","article-title":"The angiotensin type II receptor tonically inhibits angiotensin- converting enzyme in AT2 null mutant mice","volume":"57","author":"Hunley","year":"2000","journal-title":"Kidney Int"},{"key":"B89","first-page":"605","article-title":"Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin","volume":"294","author":"Marcic","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1172\/JCI7886","article-title":"Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation","volume":"104","author":"Tsutsumi","year":"1999","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1073\/pnas.022626899","article-title":"Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M106101200","article-title":"Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator","volume":"277","author":"Shariat-Madar","year":"2002","journal-title":"J Biol Chem"},{"key":"B93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00002018-200225020-00001","article-title":"Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?","volume":"25","author":"Howes","year":"2002","journal-title":"Drug Saf"},{"key":"B94","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1081-1206(10)60288-8","article-title":"Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis","volume":"101","author":"Haymore","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.amjmed.2005.06.040","article-title":"Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists","volume":"118","author":"Johnsen","year":"2005","journal-title":"Am J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1081-1206(10)60860-5","article-title":"Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"98","author":"Malde","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1751-7176.2011.00438.x","article-title":"Safety and tolerability of the direct renin inhitibor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12, 942 patients","volume":"13","author":"White","year":"2011","journal-title":"J Clin Hypertension"},{"key":"B98","first-page":"51","article-title":"Anaphylaxis: advances in the past 10 years","volume":"11","author":"Weiler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.anai.2023.04.003","article-title":"Is epinephrine truly lifesaving, and can we prove this?","volume":"131","author":"Greenhawt","year":"2023","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1302605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:28:09Z","timestamp":1706156889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1302605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":99,"alternative-id":["10.3389\/falgy.2024.1302605"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1302605","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"1302605"}}